Home

Introgen: Drug improves survival in cancer patients

By Associated Press
May 28, 2008 | Comments (0)

Recs

1

Biopharmaceutical company Introgen Therapeutics Inc. said Wednesday its drug candidate Advexin increased survival more in certain end-stage head and neck cancer patients

Introgen said that patients given Advexin in a late-stage trial who had a mutation of the p53 tumor suppressing gene, which raises the risk of developing cancer, prolonged survival by 7.2 months. In comparison, patients in the same group who were given methotrexate, a common cancer drug, prolonged survival by only 2.7 months.

The company added that both Advexin and methotrexate had similar survival benefit when all 123 patients in the trial are considered, though Advexin showed an improved safety profile.

Introgen said that the trial data will be presented at a medical conference on Thursday.

The company plans on filing an Advexin application with U.S. and European regulators by the end of June.

Shares of Introgen rose 29 cents, or more than 10 percent, to $3.09 in premarket trading.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

DocumentId: 653100, ~/articles/articlehandler.aspx, 12/1/2008 9:23:18 AM,

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.